Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:10/22/2007

working with have solid experience in conducting mid and late stage cancer trials that adhere to FDA and international standards. We have been impressed to date by the professionalism of their operations, the efficiency of their patient recruitment infrastructure and their commitment to patient welfare."

Tumor response in this new study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to ICH and GCP guidelines.

According to the World Health Organization, metastatic breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that 178,480 U.S. women will be diagnosed with cancer of the breast in 2007 and 40,460 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase ll trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer is currently undergoing regulatory review in India. A protocol for a Phase ll trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is also under regulatory review in India. Bavituximab is in clinical trials in the U.S. i
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
(Date:10/17/2014)... , Oct. 17, 2014 The ... Medical Technology Policy: The Green Park ... FDA, public and private payers, medical device and ... and other experts January 12, 2015 at its ... value of weight loss treatments.  Participants will discuss ...
(Date:10/17/2014)... , Oct. 17, 2014   InnFocus, Inc ., ... the United States for up to 3 ... Innovation Summit in Chicago . The ... beginning of the annual meeting of the American Academy ... have treated approximately 150 glaucoma patients in 6 countries by ...
Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
(Date:10/20/2014)... California (PRWEB) October 20, 2014 Final Cut ... the release of the Citrus theme for FCPX filmmakers ... would use to describe the Citrus theme” Says Christina Austin, ... easy to look so professional.” , Citrus comes with all ... with the template are: four transitions for added style, a ...
(Date:10/20/2014)... 2014 It’s hard to imagine what it’s ... vulnerable children around the world, it’s a reality. And while ... children are forced to walk barefoot on rocky terrain or ... play with their friends. , Buckner International's Shoes ... Radio in October to encourage support for Air1 and ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal ... throughout the greater Phoenix area and across Arizona reports ... to catastrophic automobile accidents. Statistics have indicated a steady ... Arizona. As such, Hastings and Hastings has seen a ... those who have been injured through no fault of ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
Breaking Medicine News(10 mins):Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... in a loss would have to pay the private sector up ... position // to fulfil the commitment to supply staff to help ... ,The trusts in the south of England were expected to second ... deal with Japanese firm Fujitsu. But the health Department has confirmed ...
... private sector employees, NHS staff take more leave per year’. ... says, about 12 days (4.5% of working days) per year seems ... in NHS. ,Bosses' organisation NHS Employers sick leave corresponds ... have planned to reduce long-term absence by launching a drive on ...
... three residents at a Eastercroft nursing home in Caldercruix, ... braced itself for possible further cases of tuberculosis after the ... ,While two of the victims died in ‘early May’ the ... resident has been reported to be recovering after being diagnosed ...
... for Health Information has found that although men experience more heart ... fatal. The study also found that women are at an increased ... the first time we know there's a difference. Now we have ... Zelmer, vice president of research and analysis for the Canadian Institute ...
... Dr. Robert Thwala, the Ministry of Agriculture Director of ... the African Regional Commission //for the International Committee of ... ,Dr. Barry O’Neil was earlier elected the President of ... elections were held last month during the 74th Annual ...
... they are forced into taking treatment elsewhere and that causes them a ... Ulster man, who had to pay thousands of pounds so that he ... the waiting list was too long to wait for. He had to ... rheumatoid arthritis. The bad part is none of them has been successful. ...
Cached Medicine News:Health News:Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project 2
Blunt tipped forceps with a smooth, pliable silicone coating on the entire interior surface of the tip. For removal of foreign bodies or atraumatic tissue grasping....
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
... and 384-well plates and strips with ... a self contained and programmable instrument, ... of precise fluidic delivery from the ... bottle to the full force of ...
... The D.O.R.C. Intraocular Electromagnet offers a truly ... ferrous intraocular foreign bodies (IOFB). Other magnets ... D.O.R.C. offers an intraocular electromagnet for use ... sky surgical technique. The D.O.R.C. Intraocular Electromagnet ...
Medicine Products: